Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.41 |
| ▸ | CDK9 | P50750 | 6/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.41 |
| ▸ | SCN1A | P35498 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17455961 | 0.89 | SCN9A (0.50) | SCN5ASCN9ASCN8ASCN1APIK3CD | |
| SCHEMBL21238932 | 0.84 | SCN9A (0.45) | SCN5ASCN9ASCN8ASCN1APIK3CD | |
| SCHEMBL17456020 | 0.84 | SCN5A (0.45) | SCN5ASCN9ASCN8ASCN1AMAP4K4 | |
| SCHEMBL17456058 | 0.78 | SCN9A (0.49) | SCN5ASCN9A | |
| SCHEMBL17456035 | 0.77 | CHRM1 (0.38) | SCN9ACCNT1CDK9MAP4K4EGFR | |
| SCHEMBL21238750 | 0.77 | CDK9 (0.51) | CCNT1CDK9EGFR | |
| SCHEMBL17455944 | 0.77 | CDK9 (0.50) | CCNT1CDK9 | |
| SCHEMBL17455963 | 0.75 | SMN1; SMN2 (0.52) | SCN5ASCN9ASCN8ASCN1A | |
| SCHEMBL12193340 | 0.74 | IKBKB (0.46) | SCN5ASCN9APIK3CDPIK3R1 | |
| SCHEMBL17456030 | 0.74 | IKBKB (0.43) | CCNT1CDK9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598398-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| EP-2982666-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024049-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | SCN5A 44/4885SCN9A 565/4885CCNT1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.